Charles River Agrees To Pay Approximately $470 Million To Expand Into Clinical Testing
Frontage operations would broaden its human-trial testing business, with up to $75 million more payable based on performance.
Charles River Laboratories, which supplies research animals, testing services and quality-control products to drug developers, agreed Monday to buy Frontage’s Exton testing operations for approximately $470 million in cash. The deal would expand its work in human clinical trials, according to the company’s announcement accompanying its SEC filing.
A Larger Role In Human Trials
Clinical-phase work currently generates approximately 15% of Charles River’s bioanalysis revenue. Frontage’s bioanalysis business had a different mix in 2025: most of its revenue came from clinical development, Charles River said in its deal announcement.
Bioanalysis examines biological samples, while drug metabolism and pharmacokinetics testing studies how the body processes a drug. The planned purchase covers those services, biomarker testing and a certified central laboratory, including capabilities for late-stage clinical diagnostic testing. Approximately 340 employees work at the two Exton, Pennsylvania, locations, which occupy approximately 150,000 square feet.
Birgit Girshick, chief executive officer of Charles River Laboratories, said clients increasingly want scientific partners able to support programs “from early development through the clinic.” She linked that need to the growing role of biologics and more complex therapies in drug-development pipelines.
Biologics and complex therapies account for approximately 75% of Charles River’s bioanalysis revenue. The company expects the purchase to broaden its small-molecule testing capabilities as well as its clinical work.
Cash Upfront, Earnings Benefits Later
The approximately $470 million initial price carries additional performance-dependent payments of up to $75 million. Charles River expects to use available cash and its credit facility to finance the purchase and associated fees.
The businesses being bought contributed approximately 40% of Frontage’s $256.7 million revenue in 2025. Charles River expects their revenue to grow over the next five years at the pace it projects for the bioanalysis sector.
That company forecast puts the market at approximately $6 billion in 2026 and approximately $8 billion to $9 billion in 2031, with annual growth of 6% to 8%. Charles River expects faster growth in biologics, complex therapies and clinical-phase testing.
Management expects no change to adjusted earnings per share from the acquisition in 2027, followed by an increase thereafter. That measure excludes acquisition-related expenses, primarily intangible-asset amortization, advisory fees, certain efficiency-program costs and third-party integration expenses.
The purchased operations would join Discovery and Safety Assessment, Charles River’s outsourced drug-discovery and regulatory safety-testing segment. That segment supplied 59.8% of the company’s $4.0 billion revenue in 2025; its other businesses provide research models and manufacturing-related testing and services.
Privatization Comes Before The Split
Charles River plans to buy the operations through a consortium with Tigermed, Frontage’s controlling shareholder, and Dr. Song Li, Frontage’s board chairman. The plan first takes Frontage private and removes its Hong Kong stock-exchange listing, then separates the businesses.
Charles River would retain the Exton bioanalysis and drug metabolism and pharmacokinetics operations. Frontage’s remaining businesses would go to Tigermed and Li or his affiliates. The consortium participant Hongkong Tigermed is a subsidiary of Hangzhou Tigermed Consulting.
Charles River expects completion in the first half of 2027. The privatization requires shareholder and regulatory approvals and sanction from the Grand Court of the Cayman Islands.
Sources
- 8-K Filing — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) — SEC EDGAR
- Exhibit dp256497_ex9901.htm — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 8-K exhibit — SEC EDGAR
- Charles River (CRL) Q3 2026 Earnings Call Transcript - The Globe and Mail — theglobeandmail.com